CN Mobile Logo


Hematologic Malignancies

MBCC 2016 hero

Hematologic Malignancies

Older patients with AML who are ineligible for intensive chemotherapy achieved improved overall survival when assigned to low-dose gemtuzumab ozogamicin.

Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.

The FDA granted approval to ofatumumab for the treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial remission after two or more lines of prior therapy.

The FDA recently expanded the drug label for carfilzomib (Kyprolis), which is now approved in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed or refractory disease who have received one to three lines of therapy.

A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.

Most adolescent and young adult survivors of Hodgkin lymphoma did not receive the recommended care within the first year post-treatment, according to a study.

A laboratory study showed that peroxisome proliferator-activated receptor gamma agonists such as pioglitazone could help treat chronic myeloid leukemia patients who are resistant or otherwise unresponsive to treatment with tyrosine kinase inhibitors.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.